Conscious humans are deliberately bred as organ supplies by 2126.

researchedcumulative

Current estimate

probability this has happened by each date

2035

<0.1%0%–0.2%no evidence yet

The founding criterion applied at 31 December 2035. Nine years, and it requires an institution to be built, operated, and externally verified inside that window. Nothing in train points at one: the nearest real practice is licensed in at least one jurisdiction and statutorily barred there from reaching a whole organ (hf-evidence-0161), the one organised attempt to source organs from human bodies lacking higher brain function procured nothing and was abandoned (hf-evidence-0162), and the only route conferring a matching advantage has never passed a human blastocyst (hf-evidence-0166). This is an error bar around zero rather than a forecast. NO INSTRUMENT CAN SCORE IT - see criterion_caveat.

2050

0.2%<0.1%–0.8%no evidence yet

The same test at 31 December 2050. Twenty-four years, which is approximately one human lead time: for this horizon to resolve true, a programme would have to be conceiving people within roughly the next five years, since a person born today is not a living solid-organ donor under any ordinary legal regime until the 2040s (hf-evidence-0169). That arithmetic is the master agent's own and not a citation. It is why this horizon stays close to 2035 rather than scaling with its extra fifteen years.

2100

0.9%0.2%–2.4%no evidence yet

The same test at 31 December 2100. Seventy-four years, and this horizon carries most of the probability mass - three or four full lead times, long enough for the xenotransplantation and cell-grown routes to either mature or disappoint, and long enough for the legal and normative architecture in hf-evidence-0165 to weaken. It is also the horizon over which the non-conscious routes in hf-evidence-0163 either arrive, in which case the claim loses its purpose entirely, or fail, in which case the pressure that this claim describes has somewhere to go.

2126 legacy

1.2%0.2%–3%no evidence yet

A verified organized program produces conscious humans principally to harvest their organs.

Resolution criteria

2035: The founding criterion applied at 31 December 2035. Nine years, and it requires an institution to be built, operated, and externally verified inside that window. Nothing in train points at one: the nearest real practice is licensed in at least one jurisdiction and statutorily barred there from reaching a whole organ (hf-evidence-0161), the one organised attempt to source organs from human bodies lacking higher brain function procured nothing and was abandoned (hf-evidence-0162), and the only route conferring a matching advantage has never passed a human blastocyst (hf-evidence-0166). This is an error bar around zero rather than a forecast. NO INSTRUMENT CAN SCORE IT - see criterion_caveat.
2050: The same test at 31 December 2050. Twenty-four years, which is approximately one human lead time: for this horizon to resolve true, a programme would have to be conceiving people within roughly the next five years, since a person born today is not a living solid-organ donor under any ordinary legal regime until the 2040s (hf-evidence-0169). That arithmetic is the master agent's own and not a citation. It is why this horizon stays close to 2035 rather than scaling with its extra fifteen years.
2100: The same test at 31 December 2100. Seventy-four years, and this horizon carries most of the probability mass - three or four full lead times, long enough for the xenotransplantation and cell-grown routes to either mature or disappoint, and long enough for the legal and normative architecture in hf-evidence-0165 to weaken. It is also the horizon over which the non-conscious routes in hf-evidence-0163 either arrive, in which case the claim loses its purpose entirely, or fail, in which case the pressure that this claim describes has somewhere to go.
2126: A verified organized program produces conscious humans principally to harvest their organs.

Probability history

Revision history for this forecast, newest first
Revised	State	p(2035)	p(2050)	p(2100)
Sep 12, 2026 hf-forecast-0206	researched	0.1% no prior revision	0.2% no prior revision	0.9% no prior revision
Sep 10, 2026 hf-forecast-0009	initial prior	—	—	—

Strongest evidence for

The coercive substrate exists now and is organised. UN special-procedure experts stated on 14 June 2021 that detainees in China may be subjected to non-consensual blood tests and organ examinations whose results are 'registered in a database of living organ sources that facilitates organ allocation', and the China Tribunal concluded in June 2019 that forced organ harvesting had occurred on a significant scale, reasoning that short wait times implied 'a bank of potential living donors who could be sacrificed to order' (hf-evidence-0164). The claim therefore does not require inventing a new kind of institution.
The specific act is nameless in law. No instrument located anywhere prohibits creating a human being for organ procurement; the binding texts that come closest were written against embryo research, reproductive cloning and bodily commodification, the Oviedo Convention is unratified by six major European states, and the two dignity-based declarations are not binding at all (hf-evidence-0165).
Humans ARE already conceived in order to supply biological material to another person - 704 cycles, 364 couples and 136 births in the largest published series - so the moral threshold of conceiving a person as a source has already been crossed and normalised in medicine (hf-evidence-0160).
The shortage is not simply resolving. United States deceased donors fell 2.5 percent in 2025, the first decline in more than a decade, against a waiting list of 109,817 (hf-evidence-0168), and cycle 14 already cut routine manufactured or engineered organs from a midpoint of 0.85 to 0.35 (hf-forecast-0199), so the comfortable assumption that the substitute simply arrives is itself no longer safe.
The horizon is a century and the claim needs one instance, and the legal architecture that would forbid it demonstrably fails to prevent adjacent conduct it does forbid.

Strongest evidence against

The nearest real practice stops at regenerating tissue and the accounting is complete. Across 136 births, all 57 resulting transplants were umbilical cord blood alone (3), bone marrow alone (17), or both combined (37) - no solid organ in any case, in a practice a quarter of a century old (hf-evidence-0160).
And the stopping point is a deliberate legislative choice rather than an accident. The United Kingdom licensed conceiving a tissue-matched child at paragraph 1ZA(1)(d) of Schedule 2 to the Human Fertilisation and Embryology Act 1990, and excluded whole organs in sub-paragraph (4) of the same paragraph (hf-evidence-0161).
The one organised attempt to source organs from human bodies lacking higher brain function failed completely: twelve anencephalic infants enrolled at Loma Linda, zero organs procured, protocol abandoned, and the American Medical Association's 1994 permission rescinded in December 1995 partly because possible awareness could not be excluded (hf-evidence-0162).
Every live proposal for a human-derived organ supply designs consciousness OUT on purpose. Renewal Bio's stated plan involves 'blocking the formation of the head, brain, or perhaps heart' and developing 'neural knockouts' described as solving 'both technical and ethical issues'; the 2025 bodyoids proposal specifies bodies engineered to lack any capacity for consciousness (hf-evidence-0163).
The medical motive for producing a person rather than using an existing donor is a perfect match, which requires cloning; human somatic cell nuclear transfer has never produced anything past a blastocyst and the best primate result is one survivor from 113 cloned embryos (hf-evidence-0166).
A bred but unrelated human is immunologically a stranger. The matching advantage is Mendelian and comes from siblinghood - one in four - or from cloning, not from breeding, and preimplantation HLA typing does not improve on the sibling rate, it selects within it (hf-evidence-0167).
The substitution arithmetic is gestation against gestation and it runs one way: a sow gestates 115 days and delivers twelve to sixteen at a time, against nine months and one, with the human barred from living solid-organ donation for roughly eighteen years (hf-evidence-0169).
The competing supply crossed from compassionate cases into regulated multi-patient trials during the year before this cycle - two phase 1/2 porcine kidney trials of fifty participants each, recruiting, with a published manufacturing capacity of up to 125 organs per year per facility (hf-evidence-0159).
No academic, policy or bioethics source found anywhere argues that breeding conscious humans for organs is a live prospect this century. The nearest published proposals argue the opposite design, and the only comparable historical claims a lane could locate turned out to be a refuted urban legend that the United States State Department publicly debunked (hf-evidence-0163, hf-evidence-0164).

Present uncertainties

Four, in descending order. FIRST and largest is definitional rather than empirical: the criterion cannot be scored, so the width above is substantially a statement about the criterion and not about the world, and under a loose reading of ORGANIZED PROGRAM the high end would be materially higher. SECOND, the consciousness argument is a claim about incentives, and incentives are not laws: an actor motivated by something other than medical efficiency - ideology, punishment, or the deliberate production of a class of persons - is not constrained by the observation that consciousness is useless for organs, and this cycle found no way to bound how likely such an actor is. THIRD, the absence results are absences from bounded searches. Four lanes looked for one session each; the null on any state ever breeding humans for a bodily product, and the null on any saviour sibling donating a solid organ, are as strong as the search that produced them and no stronger. FOURTH, a century is genuinely long for the legal and normative term, which is the one variable in this forecast with no measurement at all attached to it.

Next discriminating observation

The first documented case anywhere of a person conceived by preimplantation HLA typing donating a SOLID ORGAN to the sibling they were selected to match - in a court record, a regulator's decision, a transplant registry entry or a peer-reviewed case report, not in commentary. This is the right observation for three reasons. It is a single clock rather than a compound one, which hf-day-0016-takeaway-01 requires. It sits exactly on the line that hf-evidence-0160 measures as never crossed and hf-evidence-0161 shows one legislature deliberately drew, so it is the smallest real step from what is done to what the claim describes, and the first crossing would be strong evidence that the line is a convention rather than a wall. And per hf-day-0019-takeaway-01 its timescale is stated: this is a decade-scale observation, since the practice runs at roughly tens of cycles a year and the cohort born in 2000 is now adult and able to consent, so a null at ten years would carry real weight where a null at three would carry almost none. SECONDARILY, and as a precondition for the criterion rather than the claim: whether any registry anywhere adds a field recording the circumstances of a donor's conception, since without one this forecast cannot be scored even if the event occurs.

Sources

The competing organ supply is no longer single compassionate cases: two authorised multi-patient trials are recruiting, and the leading manufacturer has published a capacity ceiling of 125 organs per year per facility
clinicaltrials.gov · 2026 · accessed Sep 12, 2026 · trial-registry-and-company-disclosure
A live ClinicalTrials.gov API query run by the master agent on 12 September 2026 returns five porcine-organ xenotransplantation studies, two of them recruiting: NCT06878560, United Therapeutics' '10 GE Xenokidney in Patients With ESRD', phase 1/2, enrollment 50, start date 29 October 2025, status RECRUITING; and NCT07224763, the same sponsor's 'GGTA1 KO Thymokidney in Patients With ESRD', phase 1/2, enrollment 50, start date November 2026, status RECRUITING. Two more are registered and not yet enrolling - NCT07696962, ChoironeX, phase 1, enrollment 4, September 2026, NOT_YET_RECRUITING, and NCT07429838, eGenesis' EGEN-5784 porcine liver, phase 1, enrollment 20, June 2026, NOT_YET_RECRUITING - and one, NCT05340426 at the University of Alabama at Birmingham, is WITHDRAWN with enrollment 0. On manufacturing, United Therapeutics' own Organ Manufacturing Overview, updated August 2025, states that it opened the first clinical-scale designated pathogen free facility in February 2024 and expects it 'to supply xenografts for human clinical trials, with an initial capacity of up to 125 organs per year'. On durability, the longest reported pig-kidney function in a living human is 271 days, in a patient transplanted in January 2025 under expanded access, whose graft was removed in October 2025 and who then received a human kidney in January 2026.
Limit: Three limits, and the third is the largest. First, the trials are recruiting, not reporting: no multi-patient outcome data exists, and the two trials that would produce it are at 50 participants each against a United States waiting list above 100,000. Second, FDA itself has published nothing confirming either IND clearance; the clearance dates are sponsor-reported and a retrieval lane looked for an FDA-originated confirmation and found none. Third, and cutting the other way, 125 organs per year is a trial-supply figure from one facility, not a commercial ceiling - the company states further facilities are planned - so treating it as the long-run capacity of the whole route would overstate this record.
The five trial records were fetched by the master agent directly from the ClinicalTrials.gov v2 API, not from a sponsor press release and not from the rendered study page, which a retrieval lane reported returned only navigation chrome. The 125-organs-per-year sentence was extracted by the master agent from the binary of United Therapeutics' own PDF after two summarisation attempts failed to read it, and is quoted verbatim from that document. The 271-day figure and the bridge-to-allograft sequence come from Mass General Brigham's newsroom, a single institutional source, and are recorded as such.
Humans are already conceived to supply biological material to another person, 136 of them in the largest published series, and in all 57 resulting transplants the material was cord blood or bone marrow and never an organ
academic.oup.com · 2018 · accessed Sep 12, 2026 · peer-reviewed-multicentre-series
The practice exists and has a measured record. Kakourou and colleagues, reporting collaborative ESHRE data in Human Reproduction volume 33 issue 3, March 2018, describe 704 preimplantation-genetic-diagnosis cycles performed with HLA matching, from 364 couples, in which 5,532 embryos were analysed and 677 were found genetically suitable for transfer. 136 babies were born to 113 couples. From those couples, 57 haematopoietic stem cell transplants were performed, and the tissue source divides exactly three ways: umbilical cord blood alone in 3 cases, bone marrow alone in 17, and combined cord blood and bone marrow in 37. Those three numbers sum to 57, so the accounting is complete and there is no residual category. No solid organ appears anywhere in the series. Of 44 cases with transplant follow-up, 34 had no complications, one had graft-versus-host disease and one had rejection. The first case of the practice is Adam Nash, born 2000, whose cord blood was transplanted into his sister Molly.
Limit: This is a voluntary consortium submission, not a mandated registry, so it undercounts by an unknown amount and cannot be treated as a world total. It also covers 1997 to roughly 2012 in its underlying collections, so a solid-organ case after that window would not appear. The absence of an organ in the series is therefore an absence within a bounded, self-reported dataset rather than a global certainty - though it is reinforced by a separate and independent legal fact recorded as hf-evidence-0161, and a directed search by a retrieval lane for any saviour-sibling solid-organ donation anywhere returned nothing.
The cycle count, couple count, embryo counts, birth count, transplant count and the three-way tissue breakdown were re-fetched by the master agent directly from the Human Reproduction article page, independently of the retrieval lane that first surfaced them, and the figures agree across the two reads. The master's own read gives the matched-embryo share as 15.4 percent of HLA-only analyses and 11.6 percent where a monogenic disease was also excluded, against a lane figure of 12.2 percent overall, so that particular percentage is recorded as denominator-dependent rather than as one number. The Adam Nash case rests on secondary sourcing and is included as the practice's origin date, not as a figure.
The United Kingdom licensed conceiving a child to supply tissue to a sick sibling and then excluded whole organs in the next sub-paragraph, in primary legislation
legislation.gov.uk · 2008 · accessed Sep 12, 2026 · primary-legislation
Schedule 2 of the Human Fertilisation and Embryology Act 1990, as amended by the 2008 Act, contains paragraph 1ZA, which authorises licensing of embryo testing. Sub-paragraph (1)(d) permits it 'in a case where a person ("the sibling") who is the child of the persons whose gametes are used to bring about the creation of the embryo (or of either of those persons) suffers from a serious medical condition which could be treated by umbilical cord blood stem cells, bone marrow or other tissue of any resulting child, establishing whether the tissue of any resulting child would be compatible with that of the sibling'. Sub-paragraph (4) then states: 'In sub-paragraph (1)(d) the reference to "other tissue" of the resulting child does not include a reference to any whole organ of the child.' The licensing power itself was contested and upheld: the HFEA granted the Hashmi family a licence in 2002, refused the Whitaker family in the same period because no linked genetic disease could be screened, changed that policy in 2004, and the House of Lords held the Authority's decision lawful in R (Quintavalle) v Human Fertilisation and Embryology Authority [2005] UKHL 28.
Limit: This is one jurisdiction. It does not bind anywhere else, and no comparable explicit organ-exclusion clause was located in any other country's law; a retrieval lane specifically looked for a global survey of which states permit preimplantation HLA typing and could not obtain a dated authoritative one. The clause also governs what may be LICENSED, which is not the same as what is criminal: it forecloses a regulated pathway rather than punishing the underlying act, and a determined actor outside the licensing system is not addressed by it. Nor does it speak to consent given later by the resulting adult.
Both sub-paragraphs were fetched by the master agent directly from legislation.gov.uk and are quoted verbatim from the statute, independently of the retrieval lane that first reported the exclusion. The lane cited the 2008 Act's Schedule 2; the master read the amended 1990 Act's Schedule 2, which is where the operative consolidated text sits, and the wording matches. The Hashmi, Whitaker and Quintavalle history rests on secondary legal sources and is recorded as context for the licensing power, not as statutory text.
Medicine has already run the experiment of sourcing organs from human bodies lacking higher brain function: twelve anencephalic infants, zero organs procured, protocol abandoned, and the ethics guidance later reversed precisely because awareness could not be ruled out
academic.oup.com · 2005 · accessed Sep 12, 2026 · peer-reviewed-and-professional-body-statement
Loma Linda University Medical Center ran a prospective protocol from October 1987 enrolling anencephalic newborns as prospective organ donors, supporting them with intensive care for up to a week so that whole-brain death could be declared and organs lawfully taken. The Canadian Paediatric Society's position statement, in Paediatrics and Child Health volume 10 issue 6, states: 'In 1989, Loma Linda reported a study of 12 anencephalic infants who were supported with intensive care measures for one week to facilitate declaration of brain death' and that 'Successful organ donation did not occur from any of the infants.' The primary report is Peabody, Emery and Ashwal, New England Journal of Medicine, 10 August 1989, 321(6):344-50. JAMA reported the programme suspended in September 1988. The authors' conclusion, per the CPS statement, was that 'anencephalic infants could not be used as organ donors without legal and medical changes to regulate brain death and organ donation', and the CPS adds that at the time of writing 'these changes have not occurred'. The American Medical Association's Council on Ethical and Judicial Affairs issued an opinion in June 1994 permitting procurement before death and rescinded it in December 1995; contemporary reporting gives the stated grounds as doubt about diagnostic reliability and incomplete understanding of whether such infants retain some awareness. The supply side has also shrunk: the CPS states that folate fortification 'has significantly decreased the incidence of neural tube defects including anencephaly' and that 'the number of anencephalic infants born at term has decreased so much that the potential benefit from attempts to use their organs for transplantation is minimal.'
Limit: This is a single centre, one protocol, and nearly forty years old; both the diagnostic technology and the legal definition of death could change over a century. The result also speaks to a specific obstacle - anencephalic infants rarely meet whole-brain-death criteria while their organs remain usable - which is a fact about that particular condition rather than a general law about non-conscious human bodies. And the declining incidence is a fact about prevention and prenatal detection, both of which are contingent policy.
The twelve-infant enrolment, the zero-procurement result, the authors' stated conclusion and the incidence and prenatal-diagnosis statements were all fetched by the master agent directly from the Canadian Paediatric Society statement on Oxford Academic, independently of the retrieval lane that first surfaced them, and agree with it. The NEJM primary citation and the 1988 JAMA suspension notice are recorded by citation only; neither full text was reachable. The AMA reversal date and its stated reasons rest on secondary newspaper reporting, which a lane flagged when the AMA's own retrospective returned 403, and are recorded at that strength. A lane also reports one successful anencephalic heart procurement in October 1987, before the formal protocol began, so the correct statement is zero from the twelve-infant protocol rather than zero ever.
The two live proposals for growing human-derived organ supplies both design consciousness out on purpose, and one of them plans to do it by knocking out brain formation
technologyreview.com · 2025 · accessed Sep 12, 2026 · technology-journalism-and-peer-reviewed-critique
Two named, funded or authored proposals exist and both exclude consciousness by design. First, Renewal Bio, the Israeli company licensing Jacob Hanna's Weizmann Institute work, intends to grow human embryo models in rotating bioreactors and harvest tissue from them. MIT Technology Review of 21 October 2025, by Antonio Regalado, reports the models have reached 'at least 28 days' with an ambition of 'day 30 in development, day 40, or day 70', at an efficiency the article puts at 'a hundred tries to make one'. Crucially, Hanna's stated plan involves 'blocking the formation of the head, brain, or perhaps heart' by genetic modification, and the article describes researchers developing 'neural knockouts - genetic changes preventing brain development' as solving 'both technical and ethical issues'. The same article notes the 14-day rule does not legally apply to synthetic models, which Cambridge is quoted calling a 'grey area'. Second, the 'bodyoids' proposal by Carsten Charlesworth, Henry Greely and Hiromitsu Nakauchi, MIT Technology Review, 25 March 2025, proposes human bodies grown from stem cells and engineered to lack a brain and any capacity for consciousness or perception, as a source of transplantable organs - conditioned by the authors' own phrasing on whether 'the scientific difficulties could be surmounted'. A peer-reviewed rebuttal, 'No Brain, No Pain, No Problem? The Case Against Creating Human Bodyoids', appeared in Philosophy and Technology volume 38 article 164 in 2025.
Limit: These are journalism and an opinion essay, not primary research reports, and the one peer-reviewed item cited is a critique rather than a result. Neither proposal has produced a transplanted organ, neither has published a validated method for preventing neural development in a whole conceptus, and a separate lane established that no such general method exists in the literature. Efficiency at one in a hundred is a laboratory rate at 28 days, not a manufacturing rate. The regulatory 'grey area' is also unstable in both directions - it could be closed as easily as exploited.
The Hanna figures - at least 28 days, day 30 to 70, one in a hundred, the head-and-brain blocking plan, the neural-knockout description and the 14-day grey-area quote - were fetched by the master agent directly from the 21 October 2025 MIT Technology Review article and are its own words, independently of the retrieval lane whose feedback block first surfaced Renewal Bio. The bodyoids description and the authors' conditional phrasing come from a retrieval lane's read of the 25 March 2025 article, corroborated by a second lane independently, and were not re-fetched by the master. The Springer critique is recorded by title, journal, volume and article number only; both lanes reported its full text paywalled, so its arguments are not characterised here.
Coercive organ procurement is documented, organised and alleged at state scale, and in every case on record it takes organs from people who already exist rather than producing people to take them from
pmc.ncbi.nlm.nih.gov · 2021 · accessed Sep 12, 2026 · peer-reviewed-and-treaty-body-and-tribunal
The coercive substrate for this claim exists and is better documented than for most century-scale claims. On 14 June 2021 UN human rights experts said they were alarmed by reports of organ harvesting targeting minorities in detention in China, stating they had received credible information that detainees 'may be forcibly subjected to blood tests and organ examinations such as ultrasound and x-rays, without their informed consent', and that 'the results of the examinations are reportedly registered in a database of living organ sources that facilitates organ allocation'. The China Tribunal, chaired by Sir Geoffrey Nice KC, concluded in its judgment of 17 June 2019 that forced organ harvesting had been committed for years throughout China on a significant scale, and reasoned that short organ wait times 'could only occur if there was a bank of potential living donors who could be sacrificed to order'. Robertson, Hinde and Lavee, in BMC Medical Ethics on 14 November 2019, report that China's official COTRS series for 2010 to 2016 fits a quadratic curve with R-squared of 0.9993 for deceased donors, 0.9995 for kidney transplants and 0.9989 for liver transplants, and conclude the evidence 'can only be plausibly explained by systematic falsification and manipulation of official organ transplant datasets in China'. Against this, the measured commercial trade is small: UNODC reports trafficking for organ removal at about 0.2 percent of detected trafficking victims for 2010 to 2012, and roughly 700 detected victims in total between 2008 and 2022, with its own caveat that the true scale is likely larger. The most-quoted figure in this field, WHO's five-to-ten percent of kidney transplants being illicit, traces to Shimazono's provisional estimate presented at WHO's Second Global Consultation in March 2007 and published in the Bulletin of the World Health Organization that year, and no newer WHO estimate was located.
Limit: The China findings are contested by the state they concern, and the instruments carry different weights: the Tribunal is an independent people's tribunal with no legal authority, the OHCHR item is a special-procedures allegation letter rather than a fact-finding report, and the statistical paper infers manipulation from curve-fitting rather than observing it. The UNODC figure counts DETECTED victims, which is a policing artefact more than a prevalence estimate. And the WHO share is a nineteen-year-old provisional extrapolation still circulating as a current fact, which is a reason to cite it with its provenance or not at all.
The R-squared values, the journal and the falsification sentence were re-fetched by the master agent directly from the PMC-hosted BMC Medical Ethics article, independently of the retrieval lane. That re-fetch corrected the lane on two points: the journal is BMC Medical Ethics and not BMJ Open, and the fitted window is 2010 to 2016 rather than 2010 to 2018. The OHCHR quotations were verified by the master through a domain-restricted search of ohchr.org after a direct fetch returned 403, so they are OHCHR's own text reached one hop from the page. The Tribunal's conclusions and the UNODC and Shimazono figures come from a single retrieval lane and were not independently re-fetched by the master; the UNODC 2024 report PDF returned 404 for the lane.
Four instruments circle the act and none names it: the binding texts forbid creating embryos for research, reproductive cloning and profiting from the body, while the one declaration aimed at human dignity is not binding at all
coe.int · 2005 · accessed Sep 12, 2026 · treaty-and-charter-and-declaration
A directed search by a retrieval lane for any law that prohibits creating a human being for the purpose of organ procurement returned none, and the four nearest instruments each miss the act from a different direction. The Oviedo Convention, Council of Europe ETS 164, opened for signature 4 April 1997, prohibits at Article 18 the creation of human embryos for research purposes - the only binding international biomedical instrument, but addressed to embryo research rather than to a born person, and the lane reports roughly 29 of 47 Council of Europe states have ratified, with the United Kingdom, Germany, Italy, Sweden, Austria and the Netherlands outside it. The EU Charter of Fundamental Rights, Article 3, binding on member states since the Treaty of Lisbon, requires respect for physical and mental integrity and lists 'the prohibition of eugenic practices, in particular those aiming at the selection of persons', 'the prohibition on making the human body and its parts as such a source of financial gain', and 'the prohibition of the reproductive cloning of human beings' - three clauses that a bred-for-organs programme would engage by extension, none written for it. UNESCO's Universal Declaration on the Human Genome and Human Rights, adopted 11 November 1997, states at Article 11 that 'practices which are contrary to human dignity, such as reproductive cloning of human beings, shall not be permitted', and is not a treaty. The UN Declaration on Human Cloning was adopted in March 2005 by 84 votes to 34 with 37 abstentions and is explicitly non-binding, several states voting against because it conflated reproductive with research cloning. Germany's Embryonenschutzgesetz forbids producing an embryo for any purpose other than bringing about a pregnancy, which would block the embryo-stage route without naming the organ purpose.
Limit: The absence of a naming law is a weak signal in both directions and must not be over-read. Legislatures do not pre-emptively criminalise the unimagined, so the gap is at least as much evidence that nobody has tried as evidence that it would be permitted. Conversely the extension arguments are real: a prosecutor with the EU Charter's eugenics and commodification clauses, or Germany's embryo statute, would not lack material. This record establishes that the specific act is unnamed, not that it is lawful.
Every item in this record comes from a single retrieval lane and was NOT independently re-fetched by the master agent, whose verification effort this cycle went to the figures that move the forecast most. The lane's own report flags that it could not reach the Council of Europe treaty-office ratification table, returning 403, so the ratification counts are the weakest element here and are recorded as approximate. The EU Charter Article 3 clauses and the UNESCO Article 11 sentence are quoted as the lane reported them. The UN vote tally is from the UN's own press release as cited by the lane.
Human somatic cell nuclear transfer has never produced anything past a blastocyst, and in the one primate species where cloning works at all it runs below one percent
cell.com · 2024 · accessed Sep 12, 2026 · peer-reviewed
A bred but unrelated human is immunologically a stranger, so the only version of this claim that would be medically preferable to using the existing donor pool is a genetic copy of the recipient. That route has a measured ceiling. In humans, the furthest documented achievement is Tachibana and colleagues, Cell 153(6):1228-1238, May 2013, which derived karyotypically normal diploid embryonic stem cell lines from somatic-cell-nuclear-transfer blastocysts; no human SCNT embryo has been reported implanted, gestated or born, and no attempt at human reproductive cloning has been reported anywhere. In primates it works and barely: Liu and colleagues, Cell 172(4):881-887, 8 February 2018, produced the macaques Zhong Zhong and Hua Hua from fetal fibroblasts, transferring 79 SCNT embryos into 21 surrogates for 6 pregnancies and 2 live births, about 2.5 percent per embryo transferred; the parallel arm using adult cumulus cells transferred 181 embryos into 42 surrogates for 22 pregnancies and 2 live births, both of which died within 30 hours of respiratory failure. The most recent result, Liu and colleagues in Nature Communications 2024, produced one live rhesus monkey, ReTro, surviving beyond two years, from 113 cloned embryos of which 11 were transferred into 7 surrogates - under one percent from embryos created. On law, a retrieval lane reports a UNESCO-sourced count of 21 countries with legislation explicitly prohibiting human reproductive cloning and 8 more interpreting existing law as implicitly prohibiting it, against more than 150 UN member states with no such law.
Limit: Efficiency is not a permanent physical constant; somatic cell nuclear transfer improved in livestock over three decades and a century is long. The legal count also cuts the other way - most of the world has no cloning statute at all, which is the same gap hf-evidence-0165 describes. And the record's whole force depends on its premise, that matching is why anyone would breed rather than take: an actor indifferent to graft survival, or one using a bred human as an unmatched source no better than a stranger, is not constrained by any of this.
Every figure in this record comes from a single retrieval lane and was NOT independently re-fetched by the master agent; the lane reports that Cell full texts returned 403 and that it drew the macaque and human SCNT numbers from converging science-press coverage of the papers rather than the primary text. They are therefore recorded at citation strength with the primary references named so a later cycle can verify them. The Nature Communications ReTro figures were reachable and are the best-sourced item here. The 21-and-8 cloning-ban count reached the lane only through a 2022 secondary citation of an undated UNESCO source and is the weakest figure in the record.
Tissue matching is worth measurable graft-years, and the advantage comes entirely from being a sibling rather than from being bred - a bred stranger matches no better than the donor pool already does
pmc.ncbi.nlm.nih.gov · 2025 · accessed Sep 12, 2026 · registry-analysis-and-peer-reviewed
Matching matters, and its source is relatedness. An analysis of 40,371 living-donor kidney transplants performed between 1987 and 2001 with follow-up to March 2013 found that 'each additional HLA match point is associated a 1-0.996 = 0.004 lower chance of graft failure', that 'each HLA match point added an average of 0.039' kidney life years, and that 'HLA match points had the strongest relationship with' kidney life years - stronger than donor age, where 'for each year that a donor is older, the risk of graft loss is increased by 1-1.005 = 0.5%'. The Collaborative Transplant Study, over more than 150,000 recipients transplanted 1987 to 1997, reports that a fully mismatched first cadaver kidney had ten-year graft survival 17 percentage points lower than a zero-mismatch graft. Current registry figures put five-year graft survival for living-donor against deceased-donor kidneys at 90.0 against 82.2 percent for recipients aged 18 to 34 and 80.2 against 66.1 percent for recipients aged 65 and over, in the OPTN/SRTR 2023 annual report. But the mechanism is Mendelian, not manufacturable: a full sibling has a one-in-four chance of being HLA-identical by independent segregation of two haplotypes, a parent-child pair roughly one in two hundred, and an unrelated person a chance commonly put at one in a hundred thousand to one in a million. Preimplantation HLA typing does not improve on the sibling's one-in-four; it selects the embryos already inside it and discards the rest. And matching does not remove immunosuppression: a tolerance trial exists specifically to attempt withdrawal in HLA-identical sibling kidney recipients, NCT00619528, which is itself evidence that such recipients are maintained on it as standard care.
Limit: The two strongest numbers are historical: the 40,371-case cohort was transplanted between 1987 and 2001 and the Collaborative Transplant Study between 1987 and 1997, both predating modern immunosuppression, which has narrowed the matching advantage. The lane could not obtain a current SRTR figure broken out specifically for HLA-identical sibling grafts, so the modern size of the specific effect this record depends on is not established - only its direction and its Mendelian origin. The living-versus-deceased gap quoted is for any living donor, which conflates matching with organ quality and ischaemic time.
The 40,371-case cohort, the per-match-point hazard figures, the kidney-life-year coefficient and the donor-age comparison were re-fetched by the master agent directly from the PMC-hosted article and are quoted verbatim from it, independently of the retrieval lane. The SRTR five-year survival pairs and the Collaborative Transplant Study 17-point figure come from a single lane; the lane reports that the SRTR PDF tables and the PubMed abstract both returned 403, so it drew them from converging indexed summaries rather than the primary tables. The one-in-100,000-to-one-in-a-million unrelated-match figure is, on the lane's own statement, a clinical-education estimate with no cited empirical study behind it, and is recorded here as an order of magnitude rather than a measurement.
The United States performed a record 49,064 transplants in 2025 while deceased donors fell 2.5 percent, the first decline in over a decade, with more than 100,000 people still waiting
unos.org · 2026 · accessed Sep 12, 2026 · registry-and-official-statistics
UNOS, in a release dated 28 January 2026, reports that '49,064 organ transplants were performed nationwide' in the United States in 2025, a fifth consecutive annual record, while deceased donors numbered 16,550, 'a 2.5% decrease' and the first decline in more than a decade; living donors rose 3 percent to 7,237, and liver transplants set a record at 12,344. The same release states 'More than 100,000 people currently waiting for an organ transplant' and 'More than 90,000 Americans are still waiting for a lifesaving kidney transplant'. HRSA's organdonor.gov gives a list snapshot of 109,817 as of 30 July 2026, of which kidneys account for 95,492, and carries the standing framing statistic that twelve people die each day waiting. Globally the GODT 2024 report, published March 2026 from 92 reporting countries, gives 173,727 solid organ transplants worldwide in 2024 from more than 47,000 deceased donors, with donation after circulatory death accounting for 28 percent of all deceased donation activity. On waiting-list outcomes a retrieval lane reports 3,743 candidates removed for death in 2024, down from 4,734 in 2022, against 4,901 removed as too sick in 2024, up from 4,855 in 2023, and a record 49,249 new kidney candidates added in 2024.
Limit: The 2025 deceased-donor dip is one year and could be noise, a policy artefact, or the start of a trend; nothing here distinguishes those. The waiting list is also not a measure of unmet need, because listing criteria are themselves a function of expected supply, so a list that stays near 100,000 while transplants rise 23 percent over five years is partly an artefact of who gets listed. The organdonor.gov twelve-deaths-a-day figure is standing summary language rather than a dated annual count.
The 2025 transplant total, the deceased-donor count and its 2.5 percent decline, the living-donor count and increase, and both waiting-list sentences were re-fetched by the master agent directly from the UNOS release and are quoted verbatim, independently of the retrieval lane that first surfaced them; the two reads agree. The 109,817 snapshot, the GODT figures and the waiting-list removal counts come from a single lane. The lane flagged two unresolved inconsistencies it could not close and they are carried rather than smoothed: the 2024 deceased-donor count appears as both 16,988 and 16,989 across official releases, and GODT's 2024 total of 173,727 is nominally lower than its own cited 2023 figure of about 175,000 despite being described as a 2 percent record increase, most plausibly a reporting-country-count effect across 92 versus 90 countries.
A sow gestates for 115 days and delivers a dozen or more size-matchable organ donors at once; a human gestates for nine months, delivers one, and is barred from living solid-organ donation for roughly eighteen years
merckvetmanual.com · 2026 · accessed Sep 12, 2026 · veterinary-reference-peer-reviewed-and-policy
The reproductive figures on the substitute side are settled and were verified across two independent sources. The Merck Veterinary Manual states that 'the average gestation length of the pig has been increasing and now ranges 115-116 plus or minus 1 days from first service' and gives 'the usual litter size of 12-16 total born pigs'. A peer-reviewed study of 196 sows across six breeds producing 736 litters, published in Animals in 2020, reports that 'across the breeds, gestation lasted on average 115.2 days' and that 'a mean litter consisted of 12.2 piglets', with breed means from 114.7 to 118.4 days and 9.16 to 14.0 piglets. On the human side, the binding constraint on a living donor is legal rather than biological: the OPTN Ethics Committee 'supports the exclusion of minors and those incapable of making informed decisions' from living donation, and the American Academy of Pediatrics' 2008 clinical report permits minors as living solid-organ donors only in exceptional circumstances against defined criteria. A retrieval lane searching specifically for any case of a child conceived by preimplantation HLA typing serving as a solid-organ donor found none anywhere.
Limit: The comparison is not like-for-like in three ways that must be stated. A pig organ requires the gene editing and immunological work recorded in hf-evidence-0159 and has a demonstrated durability of 271 days, where a human allograft lasts years, so the pig's speed is not yet quality parity. The legal exclusion of minors constrains LIVING donation and does not by itself set the age at which a person's organs are size-matched to an adult recipient, which this cycle did not establish - a directed attempt to verify paediatric kidney growth curves was blocked and the figure is left unquantified rather than estimated. And a coercive actor is not bound by OPTN policy, so the eighteen-year term binds a lawful programme and not an unlawful one; against an unlawful one the biological term still binds.
Both pig figures were fetched by the master agent directly and independently: the gestation range and usual litter size verbatim from the Merck Veterinary Manual, and the 115.2-day mean, the 12.2-piglet mean and the 196-sow, 736-litter sample from the PMC-hosted Animals article. They agree, which satisfies the two-independent-source requirement. The OPTN Ethics Committee sentence and the AAP position come from a single retrieval lane, which reports that the OPTN policy PDF and the AAP article both returned 403, so it has the substance from indexed summaries and not the numbered policy text; the eighteen-year figure in this record's title is the ordinary age of majority and is the master's own inference from that exclusion, not a quoted number.